Categories: BrainNews

IRLAB to present at Redeye Life Science Day on November 23, 2023

GOTHENBURG, SE / ACCESSWIRE / November 20, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November 20, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present at the Redeye Life Science Day 2023 on Thursday, November 23, 2023, in Stockholm, Sweden.

Gunnar Olsson, CEO, and Nicholas Waters, EVP and Head of R&D, will participate in the event. The company will give a 2-minute pitch and then participate in a 20-minute Q&A session at 10:00-10:20 CET on November 23, 2023. This event is held at Sergelkonferensen, Mäster Samuelsgatan 42 (ground floor, Redeye building), Stockholm, and is live-streamed.

More information can be found on the event webpage at: https://www.redeye.se/events/915984/redeye-life-science-day-2023

For more information:

Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se

About IRLAB

IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinson’s disease. The company has its origin in Nobel Laureate Prof. Arvid Carlsson’s research group and the discovery of a connection between the brain’s neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed Phase IIb and is in preparation toward Phase III. Pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson’s disease. In addition, the company is also progressing the three preclinical programs IRL942, IRL757, and IRL1117 towards Phase I studies. The pipeline is driven by IRLAB’s proprietary systems biology-based Integrative Screening Process (ISP) research platform. Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se .

Attachments

IRLAB to present at Redeye Life Science Day on November 23, 2023

SOURCE: IRLAB Therapeutics

View source version on accesswire.com:
https://www.accesswire.com/806937/irlab-to-present-at-redeye-life-science-day-on-november-23-2023

Staff

Recent Posts

Methodist Le Bonheur Healthcare named among Best in Cancer Care by Money magazine

MEMPHIS, Tenn., July 5, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare announced its four Memphis-based adult hospitals…

2 days ago

Hospital PMI® at 55.8%; June 2024 Hospital ISM® Report On Business®

TEMPE, Ariz., July 5, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in June…

2 days ago

KORE Helps mCare Digital Launch the Next Generation of Personal Emergency Technology

mCare Digital unveils the mCareWatch MW-241 powered by KORE connectivity ATLANTA, July 5, 2024 /PRNewswire/…

2 days ago

Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting

Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of…

2 days ago

Hitachi’s Holography Electron Microscope Attains Unprecedented Resolution

Image acquisition and defocusing correction techniques enable observations of atomic-scale magnetic fields at never-before-seen resolution…

2 days ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical…

2 days ago